Therapeutic Potential of "Rexinoids" in Cancer Prevention and Treatment
Takemi Tanaka 1*
and
Luigi M. De Luca 2
1University of Texas Health Science Center, Institute of Molecular Medicine, Houston, Texas and 2Center for Human Nutrition, Johns Hopkins School of Public Health, Baltimore, Maryland
* To whom correspondence should be addressed. E-mail: Takemi.Tanaka{at}uth.tmc.edu.
 |
Abstract |
|---|
Retinoid X receptor (RXR) is a combinatorial partner for one third of the 48 human nuclear receptor superfamily members and acts as a master coordinator of nuclear receptor signaling pathways involved in the control of cell growth and differentiation. Thus, ligand-dependent simultaneous activation of multiple pathways is an attractive strategy for molecular-targeted therapy of neoplastic disease. However, clinical trials in RXR-targeted molecular therapy with the RXR ligand (rexinoid) have yielded disappointing outcomes. In this review, we discuss a possible mechanism underlying the loss of sensitivity to rexinoid therapy. [Cancer Res 2009;69(12):4945–7]
